The fundamental difference lies in their receptor targeting: Rybelsus activates only GLP-1 receptors, while Mounjaro works as a dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors
2 Ongoing coaching Every 2 weeks (or your preferred schedule) to review progress, manage side effects, and update your Care Plan
Patients receiving both semaglutide and anticoagulant therapy require comprehensive safety monitoring and patient education
Brief temperature excursions (a few hours at room temperature) typically cause minimal potency loss
A While the risk of hypoglycemia with Mounjaro is relatively low, if excessive dietary restrictions are implemented in parallel with Mounjaro use, symptoms of hypoglycemia such as dizziness, fatigue, and palpitations may occur
Understanding this timeline helps set realistic expectations and supports treatment adherence during the critical early months of therapy